Phase II Multicentric Study: Efficacy Evaluation of Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy on Disease-free-survival (DFS) in Patients With Resectable Head and Neck Mucosal Melanoma
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms IMMUQ
- 02 Jan 2019 Planned End Date changed from 1 May 2025 to 1 Nov 2026.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.
- 24 Oct 2017 New trial record